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Traditionally, the standard Worth Dot flashlight has been used to evaluate sensory fusion. Clinicians have 
also used the Worth Dot test in a "walk-away' manner to measure the size of a suppression scotoma in 
patients with abnormal fusion. Because the size of the flashlight targets and the distance from the patient 
are known, the practitioner can calculate the estimated size of the suppression zone. The size and 
location of this scotoma has been used to diagnose monofixation syndrome. However, there have been 
no studies to show that this suppression does not occur in patients with normal sensory fusion. The 
primary purpose of this project was to establish normative data for the normal suppression responses on 
the walk-away Worth Dot procedure. Within our sample of observers with clinically normal binocular 
vision, we found that 66% reported transitory suppression at an approximate distance of 3.7 meters and 
77% reported full suppression at an approximate distance of 4.5 meters as the Worth Dot test lantern was 
moved away. These results indicate that central suppression on the Worth Dot walk-away procedure is 
very common among normal observers. A secondary goal of this study was to determine whether the 
walk-away suppression distance is related to the response on the distance Worth Dot test. It was 
hypothesized that those subjects who showed a suppression response on the distance Worth Dot would 
also suppress at a closer distance on the walk-away. The difference for full suppression was striking: 
subjects who demonstrated suppression on the distance Worth Dot test gave a suppression response on 
the walk-away at 1.1 meters closer that those who did not suppress on the distance Worth Dot. 
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ABSTRACT 
Traditionally, the standard Worth Dot flashlight has been used to evaluate sensory 
fusion. Clinicians have also used the Worth Dot test in a "walk-away' manner to measure 
the size of a suppression scotoma in patients with abnormal fusion. Because the size of the 
flashlight targets and the distance from the patient are known, the practitioner can calculate 
the estimated size of the suppression zone. The size and location of this scotoma has been 
used to diagnose monofixation syndrome. However, there have been no studies to show that 
this suppression does not occur in patients with normal sensory fusion. 
The primary purpose of this project was to establish normative data for the normal 
suppression responses on the walk-away Worth Dot procedure. Within our sample of 
observers with clinically normal binocular vision, we found that 66% reported transitory 
suppression at an approximate distance of 3.7 meters and 77% reported full suppression at 
an approximate distance of 4.5 meters as the Worth Dot test lantern was moved away. These 
results indicate that central suppression on the Worth Dot walk-away procedure is very 
common among normal observers. 
A secondary goal of this study was to determine whether the walk-away suppression 
distance is related to the response on the distance Worth Dot test. It was hypothesized that 
those subjects who showed a suppression response on the distance Worth Dot would also 
suppress at a closer distance on the walk-away. The difference for full suppression was 
striking: subjects who demonstrated suppression on the distance Worth Dot test gave a 
suppression response on the walk-away at 1.1 meters closer that those who did not suppress 
on the distance Worth Dot. 
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INTRODUCTION 
Form fusion is the blending of form information from the two eyes. This blending 
of visual information is the driving force behind good binocularity. Fusion includes both 
motor and sensory components. On a clinical basis, motor fusion involves the amplitude, 
precision, and speed of various ranges of vergence; sensory fusion describes the response of 
fusion or suppression.1 In clinical diagnosis, sensory fusion can be classified into three levels. 
First-degree fusion, described by Worth2 as superimpC6ition of two dissimilar ocular images, 
requires stimulation of retinal areas having the same visual direction. Worth classified flat 
fusion as "second-degree fusion." Flat fusion involves true fusion of similar ocular images 
into a two-dimensional construct. Third-degree fusion is called stm:opsis and can be defined 
as, "Binocular visual perception of three-dimensional space based on retinal disparity."3 
There are many different abnormalities of sensory fusion. Central suppression is an 
abnormality that prevents or disrupts fusion of the optical images in an area surrounding the 
fovea. The edge of the suppression zone can extend to five degrees from the center of the 
fovea. Beyond this limit, suppression is considered to be peripheral. 1 Central suppression can 
be caused by small angle strabismus, anisometropia, and eccentric fixation. Central 
suppression due to eccentric fixation can usually be determined using visuoscopy. Another 
abnormality of sensory fusion is monofixation syndrome. Patients with monofixation 
syndrome have central suppression solely during binocular viewing. The diagnosis of 
monofixation syndrome includes the component of central suppression but also is 
dependent upon several other characteristics as discussed below. Differential diagnosis of 
central suppression and monofixation syndrome is important because of the difference in 
prognosis. Treatment prognosis of monofixation syndrome is generally considered to be 
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poor, while central suppression is often relatively easily managed. Therefore, it is important 
to correctly detennine the clinical diagnosis. 
Monofixation syndrome can be a difficult condition to describe, primarily due to the 
vast number of similar and overlapping definitions for closely related conditions. Some 
terms for related conditions that have evolved over the years are flick strabismus, fixation 
disparity, esophoria with fixation disparity, small angle esotropia, and retinal flicker. To gain 
a better understanding of what monofixation is, a brief historical evolution of the condition 
and its definition follovvs. The condition that is currently known as microstrabismus was 
first reported by Irvine4 in 1948. He described a syndrome where nonstrabismic 
anisometropic amblyopes produced a positive 4 base out test and whose corneal reflex 
produced reasonably good fixation. Irvine's report was followed by several other studies 
where similar conditions were described as retinal slip by Pugh5, "esophoria with fixation 
disparity'' by Gittoes-Davies6, and "fusion disparity'' by Jampolski'8• The introduction of 
the term "fusion disparity'' caused significant confusion, as the term is similar to fixation 
disparity, which was/is known as a completely different entity. In 1961, Parks reported a 
condition where the esodeviation found on alternate cover test (ACT) was larger than that 
found with unilateral cover test (UCI) . He postulated that peripheral fusion was causing the 
UCf amount to be smaller. Parks9 called this condition "monofixational phoria". The term 
monofixation syndrome, as we know it today, was introduced by Parks 10 , in 1969. He wrote 
that there are multiple causes of monofixation syndrome, the most common being 
anisometropia, small angle strabismus, and unilateral macular lesion. Unilateral macular 
lesion is probably a different entity, though, owing to the fact that it is an organic problem 
and does not resolve under monocular conditions. With macular lesions, the resulting 
fixation anomaly is probably more appropriately termed eccentric viewing. 
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Monofixation syndrome as described by Parks10•11, includes characteristics that are 
present in every monofixator and some characteristics that are only present in some 
monofixators. Parks 11 defines the constant factors to include, "straight or almost straight 
eyes with a form of binocular vision that includes peripheral fusion but an inability to 
bifixate, evidenced by a scotoma in the visual field of the non-fixating eye during binocular 
vision," and, "Fusional vergence amplitudes are always associated with the monofixation 
syndrome." The scotoma referenced here is a suppression scotoma that disappears with 
monocular testing of the affected eye, and will hereafter be termed "central suppression" in 
this paper. The variable features that Parks11 associated with this syndrome include, " ... a 
history of strabismus, anisometropia, a unilateral macular lesion, amblyopia, eccentric 
fixation, orthophoria, phoria, small tropia, possibly a larger deviation by alternate cover than 
bycover-uncovertest." Also, "The majorityof the patients with monofixation syndrome 
have gross stereopsis ... ". In addition, it has been stated by Griffin and Grisham\ that the 
deviation seen in monofixation syndrome is most commonly an eso deviation. Parks 12 
defines this further as "... of the strabismic patients who develop the mono fixation 
syndrome after treatment, approximately 90 percent are esotropes and 10 percent are 
exotropes". 
Depending on the factors present, the diagnosis of monofixation syndrome can 
include a variety of tests. The basis for the diagnosis is in the characteristics present10•11 : a 
suppression scotoma of approximately 3 degrees, peripheral fusion with fusional vergence 
amplitudes, and gross stereopsis of 60 to 3000 seconds of arc. The unilateral cover test will 
show a horizontal fixation movement between zero and eight prism diopters and a vertical 
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between zero and three prism diopters . Alternating cover test may show all possible 
responses: phoria, identical deviation to the unilateral, or greater deviation than unilateral. 
Therefore, no single response on the cover test is sufficient to identify the syndrome. Parks 10 
states that, "the diagnosis of mono fixation syndrome can be made only by sensory 
investigation". This sensory investigation should reveal the characteristics of the syndrome. 
A proposed flow chart for the diagnostic testing for monofixation syndrome is shown in 
Figure One. 
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No Movement or <8~ 
>8~ Eso/Exo~Strabismic 
Figure 1. Proposed flow 
chart for the diagnosis of 
Monofixation Syndrome 
Orthophoria, Movement ~ Unilateral CT 
Non Fusion Response 
Fusion Response 
Loss of Fusion At> 2 meters~Normal 
Loss of Fusion at < 2 meters 
Superimpose Test and Fusion Targets~ Bifixator 
Test Target Disappears within 1.5-2.5° of Fixation Target 
Ba£olini Striated Lens Test 
Gap Seen Within the Streaks 
(Scotoma= 3-5°) 
Stereopsis 3000" -67" of Arc 
n 
No Gap Seen within the Streaks 
Better than 67" of Arc 
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Figure 2. Diagram of the Worth Dot test flashlight used in this study for the walk-away 
testing. The dimensions of this test were: four 6-rnillimeter colored dots spaced equidistant 
around a 34-millimeter diameter circle. 
Figure 3. Diagram of the Distance Worth Dot test with dimensions of four 4-centimeter 
colored dots spaced equidistant around a 30-centimeter diameter circle. 
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Clinicians have also used the Worth Dot test in a "walk-away'' manner to locate the 
size of the central suppression. It is best to begin the test at near with a handheld Worth Dot 
test lantern and move away from the patient14• If the patient sees all four dots at near, the 
practitioner slowly moves away from the patient to the distance the patient reports 
suppression. Because the size of the flashlight targets and the distance from the patient are 
known, the practitioner can calculate the estimated size of the suppression zone. However, 
the literature includes no data to differentiate normal from abnormal suppression responses 
on the walk-away test. Thus, practitioners are left to use only their subjective clinical 
experience to detennine normal from abnormal. 
Because of the lack of this diagnostic data in the literature, the primary purpose of 
this project was to establish normative data for the normal suppression responses on the 
walk-away Worth Dot procedure. Secondary goals of the study were to determine whether 
the walk-away suppression distance correlated with the response on the distance Worth Dot 
test (Figure 3) and the responses on the BV AT acuity suppression test. 
METHODS 
The project was conducted in the Pacific University College of Optometry Vision 
Therapy Service, in Forest Grove, OR. There were three steps in the research protocol. Each 
of these steps occurred in a different clinic exam room The first room included completion 
of the Informed Consent Form (Appendix 1) and the Study Intake Forms (Appendix 2). The 
pre-study screening took place in the second room. This room included a standard 
optometric exam lane and the Binocular Visual Acuity Teste~. The third room was where 
the Worth Dot testing occurred. Each exam room had closed doors to ensure that the 
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subjects remained isolated from each other and had no prior knowledge of the study 
procedures or results . The experimenter that conducted the Worth Dot testing also had no 
prior knowledge of the subject's screening results. The ambient light level of the pre-study 
testing and the Worth Dot study rooms was determined to be 53 foot candles, as measured 
with a General Electric Type 213 photometer. 
Sixty-five volunteer subjects were recruited from the first-year optometry class at 
Pacific University College of Optometry. There were 32 female and 33 male subjects and 
their ages ranged from 21 to 36 years. The study took place during the third week of class, 
when they were nai've to the Worth Dot test. Subjects first completed and signed the 
Informed Consent Form that described the study and its risks and benefits. Medications, 
history of ocular trauma/ disease, and any systemic disease conditions were recorded by each 
subject on the Study Intake Form prior to the testing. The subjects' refractive condition was 
determined by one of the following methods: 
1. Documentation of current prescription 
2. Verification of current spectacle prescription with lensometry 
Subjects were then tested to ensure that each met the following inclusion criteria. 
• Absence of any systemic disease, ocular disease, or ocular trauma that might affect the 
outcome measure. 
• Absence of any prescription pharmaceutical effect on visual function in regard to the 
study. 
• Habitual (unaided or aided) visual acuity of at least 20/25 in each eye, tested at 6m and 
40 em with a Snellen projection slide and Snellen near point card, respectively. 
A BVAT; Mentor Ophthalrnics Inc. 
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• Refractive condition of less than +1- 6.00 diopters sphere and less than 2.50 diopters of 
cylinder. 
• Anisometropia of less than 1.00 diopter. 
• Stereo acuity of at least 100 seconds of arc tested with the W1rt Circle near-point test. 
• Heterophoria shown on distance and near cover tests. 
• Normal response on an initial Worth Dot test at 33 em. 
The BVAT visual acuity suppression test was done after the completion of the 
inclusion criteria testing. The level of central suppression was measured using Snellen-type 
letters that were presented so that some were seen only by the right or left eye while others 
were seen by both eyes. A sample of the stimuli is illustrated below (Figure 4): 
Stimuli: 
Seen by. 
F 
ou 
z 
OS 
B 
ou 
D 
OD 
E 
ou 
The size of each line of letters was gradually reduced until the subject reported that one of 
the letters had disappeared. The visual acuity demand at which this suppression was first 
reported was recorded. 
Fifty-four of the sixty-five volunteers met the inclusion criteria and proceeded 
individually to room three where fusion was assessed with the walk-away Worth Dot test 
and with the distance Worth Dot test. The Worth Dot test lantern used had dimensions of 
four 6-millirneter colored dots spaced equidistant around a 34-millimeter diameter circle 
(Figure 2), which is the typical clinical stimulus13 • This target size subtends a 6-degree angle 
on the retina of the subject at 33 em and a 0.33-degree angle at 6m. The Worth Dot test 
lantern batteries were replaced every ten subjects. The subjects wore anaglyphic glasses over 
their habitual lenses with the red lens worn over the right eye and the green over the left. 
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Subjects were seated facing the experimenter as the follo-wing instruction set was read to the 
subject: 
"How many dots do you see? What color are the dots? I am going to slowly move back away 
from you. As I do I want you to pay attention to two things. First, I want you to notice how 
many dots you are seeing and if the number changes, tell me what you see. Second, I want 
you to notice the colors of the dots you see and if the colors change, tell me what you see. 
Do you have any questions about these instructions?" 
The experimenter began with the Worth Dot flashlight at a distance of 33 em from 
the subject, then moved back along a tape measure at a rate of ten em/ second to a distance 
of 6 m or the distance where abnormal fusion (suppression or diplopia) was reported. The 
patient was instmcted to blink every three seconds. Blink rate was controlled by the 
instruction set and experimenter observation. Each subject's gaze was maintained in primary 
position throughout testing. Measurements were taken from the front of the cornea to the 
front surface of the Worth Dot flashlight. The distance where abnormal fusion was reported 
("first suppression") was recorded as the limit of normal sensory fusion. The subject was 
instructed to blink several times, and if normal sensory fusion returned the experimenter 
continued to move backward until fusion could no longer be recovered with blinking ("full 
suppression"). This distance was recorded. This process was repeated three times and the 
resulting distances averaged for each subject. 
After the walk-away Worth Dot test was complete, each subject was shown the 
distance Worth Dot test to determine whether the subject was fusing or suppressing the 
target at 6 meters. The distance Worth Dot test had dimensions of four 4-centimeter colored 
dots spaced equidistant around a 30-centimeter diameter circle (Figure 3). The distance 
Worth Dot lantern was 6 meters from the subject in primary gaze. This test condition 
created an angular subtense of 3 degrees on the retina. The subject was asked, "How many 
dots do you see? What color are the dots?" The responses were recorded. 
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RESULTS 
Table 1 shows the descriptive data for the tested subjects. The mean refractive 
condition for the sample studied was approxirnately-1.87 D sphere and -0.25 D cylinder. 
Habitual distance and near visual acuities were very precise with means of 20/15 and 20/20, 
respectively. The standard near Snellen card was limited at 20/20. The subjects also 
demonstrated good stereo acuity measured at 40cm with a mean of 40 sec arc. 
Test Sphere ' Cylinder Sphere Cylinder DVA DVAOS NVA NVA Stereo 
OD (D) OD (D) OS (D) OS (D) OD 20/ OD OS (sec arc) 
20/ 20/ 20/ 
Mean -1.88 -0.27 -1.87 -0.23 15.7 15.6 20 20 41.7 
Std. Dev 2.00 0.45 2.05 0.45 2.45 2.31 0 0 4.2 
Table 1. Refraction, visual acuity and stereo acuity for the tested subjects. 
The suppression data for the walk-away Worth Dot test are described in Table 2. 
The number of subjects demonstrating either first suppression or full suppression was 
statistically examined. Chi square analysis showed that there were significantly (P <0.001) 
more subjects who showed both first and full suppression responses than those who did not. 
First Suppression Full Suppression 
n mean s.d. %that n mean s.d. %that 
(m) (m) suppressed (m) (m) suppressed 
Triall 34 3.65 0.747 63% 41 4.49 1.14 76% 
Trial2 37 3.73 0.752 69% 42 4.55 1.15 78% 
Trial3 36 3.65 0.792 67% 42 4.51 1.13 78% 
Mean 3.68 0.763 66% 4.52 1.14 77% 
Table 2. Results of walk-away Worth Dot Testing. Then's represent the number of 
subjects who suppressed in each condition on each trial. The means represent the average 
distance at which suppression occurred for those subjects who suppressed. The percentages 
represent the percent of the sample who suppressed on any given trial. 
Subjects were divided into two groups based upon whether or not they 
demonstrated abnormal fusion on the Distance Worth Dot test. The distance at which 
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abnormal fusion occurred on the walk-away Worth Dot test was then compared for these 
two groups using t-test analysis. The data are shown in Table 3. It can be seen that the 
distance at which full suppression occurred on the walk-away was significantly (P =0.0011) 
closer for those subjects who had abnormal fusion on the Distance Worth Dot. The distance 
at which first suppression occurred on the walk-away nearly differed (P =0.0625) between the 
groups, again suggesting that subjects who had abnormal fusion on the Distance Worth Dot 
tended to suppress with larger targets (i.e., at closer distances) on the walk-away. 
Avera~ e First Suppression Average Full Suppression 
n mean (m) s.d. (m) n mean (m) s.d. (m) 
Suppression 12 3.27 0.620 14 3.79 0.914 
OnDist. WD 
No Suppression 29 3.75 0.772 29 4.92 1.02 
OnDistWD 
Probability Df =39 Df =41 
TValue = -1.918 T Value = -3.497 
Probability = 0.0625 Probability= 0.0011 
Table 3. Distance at which suppression occurred on walk-away Worth Dot compared to the 
presence or absence of suppression on distance Worth Dot testing. Then's represent the 
number of S's who suppressed or did not suppress on the distance Worth Dot. The means 
indicate the distance at which first suppression or full suppression occurred on the Worth 
Dot walk-away for those same subjects. 
Regression analysis was completed to determine whether subjects who suppressed at 
a lesser distance on walk-away Worth Dot testing also suppressed at a larger acuity value on 
the BVAT. The results of the BVAT testing were clustered with all subjects' first 
suppression between 20/15 and 20/40. Whereas, the results of the walk-away Worth Dot 
test were quite variable. The lack of variability and leptokurtosis in the BVAT results made 
the comparison between the two sets of data invalid. 
17 
DISCUSSION 
The primaty purpose of this project was to establish normative data for the normal 
suppression responses on the walk-away Worth Dot procedure. Within our sample of 
observers with clinically normal binocular vision, we found that 66% reported transitory 
suppression at an approximate distance of 3.7 meters and 77% reported full suppression at 
an approximate distance of 4.5 meters as the Worth Dot test lantern was moved away (Table 
2). The angular sizes corresponding to these test distances is shown in Table 4. These 
results indicate that central suppression on the Worth Dot walk-away procedure is very 
common among normal observers. Therefore, if the Worth Dot walk-away procedure is 
used in the diagnosis of monofixation syndrome, the clinician must demonstrate Worth Dot 
suppression at distances much closer than we found in order to show evidence of abnormal 
central suppression. 
Distance of Worth Dot 
Flashlight (m) 
0.33 
0.50 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
5.5 
6.0 
Angular 
Sub-tense ( deg) 
6 
4 
2 
1.3 
1 
0.8 
0.7 
0.6 
0.5 
0.43 
0.40 
0.35 
0.33 
First Suppression Mean = 0.54 degrees 
Full Suppression Mean= 0.43 degrees 
Table 4. Nomogram showing the conversion 
from the Worth Dot walk-away suppression 
distance to the ant}Ular subtense of the 
suppression zone. 
Significantly more subjects suppressed on the walk-away Worth Dot test than did 
not in our sample. Based on our data, an estimate of the range (mean ± 1 s.d.) of "normal" 
central suppression responses for first suppression was 2.9 -4.4 m, and for full suppression, 
3.4 - 5.7 m. If the clinician desires a more conservative estimate (mean- 2 s.d.) of abnormal 
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suppression distance, the values are 2.2 meters for both first suppression and full 
suppression. Based upon these values, a consetvative clinical rule of thumb for abnormal 
suppression on the Worth Dot walk-away procedure is: Any suppression that occurs at a 
distance closer than two meters should be viewed as distinctly abnormal. The nomogram in 
Table 4 sho-ws that this two meter distance corresponds with an angular subtense of one 
degree, approximately equal to the angular subtense of the foveal area. 
This rule of "suppression inside two meters is abnormal" must be considered in light 
of variability in subject interpretation. It was obsetved that many subjects had difficulty 
determining if or when they regained fusion after first suppression. Some subjects also had 
trouble specifying whether they completely lost fusion or if there was a fluctuation between 
fusion and suppression. Given that our young adult subjects had difficulty with these 
distinctions, the clinical challenges of interpretation for pediatric patients are not 
insignificant. 
A secondary goal of the study was to determine whether the walk-away suppression 
distance is related to the response on the distance Worth Dot test. It was hypothesized that 
those subjects who showed a suppression response on the distance Worth Dot would also 
suppress at a closer distance on the walk-away. This hypothesis was borne out for both first 
suppression and full suppression. The difference for full suppression is striking: subjects 
who demonstrated suppression on the distance Worth Dot test gave a suppression response 
on the walk-a-way procedure that occurred 1.1 meters closer than those who did not suppress 
on the distance Worth Dot. These results suggest the obvious: if the clinician chooses not 
to take the time to perform the Worth Dot walk-away procedure, useful information 
concerning central suppression can be gleaned by simply asking the patient to respond to the 
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distance Worth Dot test. This approach does not enable the clinician to estimate the size of 
the central suppression zone, but does provide at least nominal suppression information. 
A more comprehensive study is recommended to enhance the clinical relevancy of 
this experiment. Such a study should include a larger and more diverse subject pool in the 
normative analysis. In order to test the validity of the "normal" suppression distances 
presented here, future studies should include subjects who have been definitively diagnosed 
with monofixation syndrome and perhaps other related anomalies. It would also be 
interesting to determine the other tests that are most commonly used in the clinical diagnosis 
of monofixation syndrome, and how those tests correlate with the Worth Dot procedures 
we studied. 
Because a sensory evaluation is imperative in the diagnosis of mono fixation 
syndrome, it is important to have a convenient clinical test that can be used in both specialty 
and primary care practice. Many practitioners already use the Worth Dot test as a quick and 
easy test of sensory fusion. Using the normative data for the walk-away Worth Dot 
procedure presented here, practitioners can have more confidence in their diagnosis of 
abnormal fusion in monofixation syndrome. By using an instrument that is familiar to many 
doctors, the number of false positive diagnoses of monofixation syndrome can be reduced. 
More precise diagnosis of monofixation syndrome will result in more accurate prognosis and 
treatment for those patients. 
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No Movement or <86. 
>86. Eso/Exo~Strabismic 
Figure 5. Recommended flow 
chart in the determination of a 
diagnosis of monofixation 
syndrome. 
Orthophoria, Movement ?:: Unilateral CT 
Non Fusion Response 
Fusion Response 
Loss ofFusion At> 2 meters~ Normal 
Loss of Fusion at< 2 meters 
D 
cJ Superimpose Test and Fusion Targets~Bifixator 
Test Target Disappears within 1.5-2.5° of Fixation Target 
Bagolini Striated Lens Test 
Gap Seen Within the Streaks 
(Scotoma = 3-5°) 
Stereopsis 3000"-67" of Arc [l 
No Gap Seen within the Streaks 
Better than 67" of Arc 
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Appendix 1. 
INFORMED CONSENT FOR P ARTIOPATION IN A RESEARa-I PROJECT 
Pacific University College of Optometry 
A Title of Project: Should the Worth Dot test be used to diagnose rnonofixation 
syndrome? 
B. Investigators: 
Study Monitors: 
Bradley Coffey, OD, FAAO 
Pacific University College of Optometry 
Amanda Galster and Kristi DeJong 
C. Location: Pacific University College of Optometry Vision Clinic, 
Forest Grove, OR 
D . Date: August 2002 to May2003 
E. Description of Project: In this study, we will investigate sensory fusion using the 
Worth Dot test as a way of diagnosing rnonofixation syndrome. Initially, common 
clinical distance and near tests will be performed to determine if subjects meet the 
study criteria. If the criteria are met, the subjects will be tested for sensory fusion 
from a distance of 33 ern to 6 rn using the Worth Dot flashlight. 
F. Description of Risks: The only known risks are associated with being in the location 
where the experiment is being conducted, putting on the red-green glasses and 
Binocular Visual Acuity Test (BVA1) goggles, and having confidential information 
released. 
G. Description of Benefits: Results of this project will be used for evaluating the 
efficacy of the Worth Dot test in the diagnosis of rnonofixation syndrome. The data 
obtained will serve as a normative baseline of fusion and suppression in subjects with 
normal sensory fusion. 
H Alternatives advantageous to Subjects: There are no additional alternative procedures 
or courses of treatment. 
I. Confidentiality: Records of this project will be maintained in a confidential manner 
and no name-identifiable information will be released. 
J. Compensation and Medical Care: If you are injured in this experiment and it is not 
the fault of Pacific University, the experimenters, or any organization associated with 
the experiment, you should not expect to receive compensation or medical care from 
Pacific University, the experimenters, or any organization associated with the 
expenrnent. 
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K. Offer to Answer Inquiries: The experimenters will be happy to answer any questions 
you may have at any time during the course of this study. If you are not satisfied with 
the answers you receive, please call Dr. Karl Gtek at 503-352-2126. During your 
participation in the project you are not a Pacific University clinic patient or client and 
all questions should be directed to the researchers and/ or the faculty advisor who 
will be solely responsible for any treatment (except in an emergencyry . You will not be 
receiving complete eye, vision, or health care as a result of participation in this 
project; therefore, you will need to maintain your regular program of eye, vision, and 
health care. 
L. Freedom to Withdraw: You are free to withdraw your consent and to discontinue 
participation in this project at any time without prejudice or consequences to you. I 
have read and understand the above. I am 18 years of age or over or this form is 
signed by and my parent guardian and me. 
Printed name of subject- ----- ---------- -
Subject's signature ____________ _______ _ 
Printed name and signature of parent or guardian if subject is under 18 years of age: 
Address 
--------- -------- ---------
Gty/State ------- ---------- -----
2~------------------------
Phone 
--------- - ------ ---- -------
Date 
-------------- ----------- --
Name and address of a person not currently living with you who will always know how 
to locate you: 
Printed name and signature of interpreter if required: 
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Appendix 2. 
STUDY INTAKE FORM 
Full Name 
Glasses/ Contact Lens Rx: R L: 
Medications and Reason for Taking it: 
Eye Health History: Please circle below if you have any of the following: 
Glaucoma Cataracts Macular degeneration Eye tum Lazy Eye 
Please state the type of injury, surgery, or infection and when it occurred. 
Eye injury 
Eye surgery 
Eye infection 
Medical Health His t01y: Please circle below if you have any of the following: 
Diabetes 
High blood pressure 
Heart problems 
Thyroid problems 
Cancer 
Liver problems 
Kidney problems 
Stomach problems 
Netve problems 
HIV/AIDS 
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